Parent drug / active metabolite

Pharmacokinetics

Ibogaine clears on one timeline. Noribogaine follows on another. That difference helps explain why a short acute experience can be followed by a much longer period of measurable drug-related exposure.

A half-life is not a promise of a “reset.”

A behind-the-scenes view accompanying the distinction between ibogaine and noribogaine timelines — Two clocks, not one: parent compound + metabolite.

01 / starting point

The parent drug is only part of the story.

After oral administration, ibogaine is absorbed and reaches measurable blood concentrations over hours rather than remaining confined to the gut. Human studies have reported peak ibogaine concentrations within roughly 1–3 hours, while noribogaine commonly peaks later as metabolism proceeds. These are observed pharmacokinetic patterns, not a schedule that applies uniformly to every person.

Ibogaine is lipophilic and distributes beyond plasma into tissues. It is then metabolically converted to noribogaine, a compound with distinct pharmacology and a longer reported elimination timeline. For a basic orientation to what is meant by ibogaine therapy, the wording on ibogaine therapy as a term is useful only when separated from claims about efficacy or safety.

“Lasting” can refer to a reported experience, a behavioral outcome, a receptor-level hypothesis, or a measurable molecule. Those are not interchangeable.

02 / cut + convert

Absorption, distribution, conversion.

Pharmacokinetics asks what the body does to a compound: how it enters circulation, moves through the body, changes chemically, and is eliminated.

A visual accompaniment to metabolic conversion from ibogaine to noribogaine — The metabolite arrives on a delayed curve.

One pathway, variable pace

Cytochrome P450 2D6 (CYP2D6) is an important enzyme in the conversion of ibogaine to noribogaine. CYP2D6 activity varies between people because of genetic differences and because some medicines inhibit the enzyme. The NCBI overview of CYP2D6 pharmacogenetics describes why metabolic phenotype can change drug exposure and metabolite formation.

That variability matters to interpretation: a person with slower CYP2D6 activity may show a different parent-drug and metabolite pattern than a person with typical or faster activity. It does not establish a predictable subjective effect, a benefit, or an individual safety margin. Broader discussions of ibogaine’s botanical origins do not substitute for measured plasma concentrations of a defined preparation.

Different metabolism ≠ a dependable outcome.

03 / figures with footnotes

Reported half-lives: parent vs. metabolite.

Published human data are limited, but the recurring finding is a substantially shorter apparent half-life for ibogaine than for noribogaine. A half-life is the estimated time for a measured concentration to fall by half during a specified phase of elimination; it is not the duration of a clinical effect.

Ibogaine: In a small human pharmacokinetic study by Mash and colleagues, apparent terminal half-life estimates for ibogaine were on the order of about 4–7 hours. Estimates depend on the sampling schedule and model used, so they should be read as study-specific rather than universal.
Noribogaine: In that literature, noribogaine has often been reported with a much longer apparent terminal half-life, approximately 28–49 hours. Its later peak and slower decline mean it can remain detectable after parent ibogaine has fallen substantially.
Plasma levels: A molecule may persist through several half-lives, but “pharmacologically relevant” has no single threshold that can be carried from one study, receptor, or person to another. Measurable concentration is not proof of a months-long intervention effect.
Why months are different: A 28–49 hour terminal half-life can support exposure over days, not a direct pharmacokinetic explanation for effects described months later. Those claims need outcome studies with their own methods and follow-up.
Clinical context: Ibogaine has recognized safety concerns, including potentially serious cardiac risks. The FDA’s ibogaine safety information notes that it is not approved for medical use in the United States.
Language matters: Discussions of a street-name framing can obscure what pharmacokinetic studies actually measure: concentrations, time points, assays, and fitted curves—not a cultural label or a cure claim.

04 / limits in the margins

What the existing studies cannot settle.

The evidence base for ibogaine pharmacokinetics is informative but narrow. Small datasets are useful for describing observed concentration-time profiles; they are not a shortcut to broad clinical conclusions.

Small samples, shifting measurements

Human ibogaine studies have often involved small samples, different formulations and doses, varying participant histories, limited sampling windows, and different assay methods. Those design choices can change estimated peak concentrations and terminal half-lives. The broader concept of pharmacokinetics is built around this kind of concentration-over-time interpretation, not a single number detached from its method.

Reported longer-term changes after ibogaine also cannot be assigned to noribogaine levels alone. Post-acute context, expectation, concurrent care, withdrawal patterns, selection effects, and follow-up loss can all shape reported outcomes. Readers comparing claims of ibogaine therapy benefits should keep the exposure data separate from outcome claims.

Neither a pharmacokinetic estimate nor a personal story answers practical questions about suitability or risk. Resources that discuss long-term side-effect questions are most useful when they preserve uncertainty instead of treating a half-life as a safety guarantee.

“Reset” is not a PK endpoint

When people say a reset lasts for months, they may be describing a meaningful personal change. That observation is not invalidated by a shorter plasma timeline. But it is also not established by it. Parent-drug disappearance and metabolite persistence are biological exposure measures, while sustained changes are separate outcomes requiring controlled, transparent follow-up.

The site’s mechanisms discussion follows that distinction: plausible pathways are hypotheses, not confirmation that a particular experience will endure. For an overview of the questions this resource is built to separate, return to the Brass Moth starting page.

Evidence can be limited without being meaningless.

Does a long noribogaine half-life prove that ibogaine produces a lasting reset?

No. Persistence of a metabolite in plasma describes exposure, not a guaranteed clinical outcome. Longer-term reports require their own evidence and should be separated from pharmacokinetic findings. This distinction is especially important when comparing marketing-oriented lists of ibogaine treatment centers with the underlying evidence.

Why do published ibogaine half-life estimates differ?

They can differ because studies use small samples, different dose forms, sampling windows, analytical assays, participant characteristics, and pharmacokinetic models. CYP2D6 activity and interacting medicines can also affect the balance between ibogaine and noribogaine exposure. Localized information such as ibogaine treatment in Texas should not be mistaken for a source of universally applicable pharmacokinetic data.

Can plasma persistence tell someone what to do?

No. This page describes published pharmacokinetic findings, not clinical recommendations. Individual risk can be affected by medical history, cardiac factors, other substances, medications, dose, and monitoring conditions. Questions about access or location, including where ibogaine treatment is available, are separate from evidence about drug disposition and do not replace medical or legal advice.

Keep claims beside their limits.

A pharmacokinetic timeline can clarify what was measured. It cannot by itself tell the story of recovery, risk, or lasting change.

See the practical limits →